Every 424B that Praxis Precision Medicines, Inc. (PRAX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow PRAX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRAX filings page.
Praxis Precision Medicines, Inc. is issuing 2,212,000 shares of common stock at $260.00 per share in an underwritten public offering, with underwriters holding a 30-day option to buy up to 331,800 additional shares. The deal is expected to generate approximately $540.1 million in net proceeds, which, combined with about $925 million in cash, cash equivalents and marketable securities as of December 31, 2025, is expected to fund operating needs into 2028.
The company plans to use the cash to prepare for potential commercialization of late-stage product candidates, continue clinical development, advance earlier-stage CNS programs, and for general corporate purposes. Shares outstanding will increase from 25,195,092 to 27,407,092 after the offering (excluding the option), and new investors face dilution of $222.20 per share based on an as adjusted net tangible book value of $37.80 versus the $260.00 offering price.
Praxis Precision Medicines, Inc. is conducting a primary offering of common stock and pre-funded warrants to raise cash for its neurology drug pipeline. The company will sell newly issued shares and, for certain investors, pre-funded warrants that are exercisable at $0.0001 per share, with ownership caps to limit any holder’s voting stake. As of December 31, 2025, Praxis reported preliminary cash, cash equivalents and marketable securities of approximately $925 million, giving it substantial funding alongside the new capital raise. The company expects to use proceeds, together with existing cash, to prepare for potential commercialization of late-stage product candidates, continue clinical development, advance earlier-stage programs and fund general corporate needs.
Praxis Precision Medicines (PRAX) launched a primary offering of 3,025,480 shares of common stock at $157.00 per share and pre-funded warrants to purchase up to 318,470 shares at $156.9999 per underlying share. The company expects gross proceeds of $525,000,118.15, underwriting discounts of $31,500,009.00, and proceeds before expenses of $493,500,109.15. Underwriters have a 30-day option to buy up to 501,592 additional shares.
The company estimates net proceeds of approximately $493.0 million and plans to use them, together with existing cash, to fund R&D, prepare for potential commercialization of late-stage assets, advance earlier-stage programs, and for working capital and general purposes. Shares outstanding were 21,165,933 as of September 30, 2025, and are expected to be 24,191,413 immediately after the offering, excluding shares issuable upon exercise of the pre-funded warrants. The pre-funded warrants are exercisable at any time, carry a $0.0001 exercise price, and are subject to a 4.99% (or 9.99%) beneficial ownership limitation.
Praxis Precision Medicines launched a primary offering of common stock and is also offering pre-funded warrants, with an underwriters’ 30‑day option to buy additional shares. The pre-funded warrants carry a $0.0001 per‑share exercise price and are subject to ownership limits. Proceeds are earmarked for R&D, late‑stage commercialization preparation, earlier‑stage programs, working capital and general corporate purposes.
The company reported positive topline Phase 3 Essential3 results for ulixacaltamide in essential tremor. In Study 1, the primary endpoint showed a 4.3‑point mean improvement in mADL11 at Week 8 (p<0.0001), sustained through 12 weeks, with all key secondary endpoints statistically significant. In Study 2, 55% maintained response on ulixacaltamide vs 33% on placebo (p=0.0369; OR=2.7).
Safety was generally consistent with prior experience: most common adverse events included constipation, dizziness, euphoric mood, brain fog, headache, paraesthesia and insomnia; there were no deaths and no drug‑related serious adverse events. Praxis has submitted a pre‑NDA meeting request to the FDA and plans to submit the NDA by early 2026.